MomentumOptionsTrading.com Weekly Wrap for 9/11/11
10:00pm (EST)
1. Market Summary
2. NetEase.com (NTES) a Good Play on China’s Online Gaming Boom
3. Vivus (VVUS) Shares Showing Some Momentum
4. Earnings
5. Weekly Wrap Portfolio Update
6. Week Ahead
(To view the charts, please log into the Members Area and go to the Weekly Wrap Premium section)
= = = = = = = = = = = = = = =
1. Market Summary –
Remembering 9/11….
The bears went into the shortened holiday week with a little momentum from the previous week and used it to push the market lower on Tuesday. Futures were signaling a terrible open and a quick test down to key support levels which had Wall Street on edge. To settle down things, the NYSE actually invoked Rule 48 which could have led to a delayed open or “reopening” on a halt but the market started on time. However, the major indexes fell below key support levels within the first 15 minutes of trading. The Dow dropped below the 11,000 mark and the S&P gave up 1,150. The Nasdaq was a stone’s throw from 2,400 before all 3 bounced back in the final 15 minutes of trading.
The strong rebound carried over into Wednesday’s session and the bulls went wild. There were no real catalysts for the rebound except for what the President might or might not say on Thursday. The test down to support and the lower end of the current trading range was met with buyers just like it has been for over 6 weeks now. This time was a little different because the surge was incredible as the market moved up nearly 3% and was back at resistance. The trip to the bottom and back to the top took 2 days. We did remind everyone that volatility would be here for awhile right?
We figured Thursday would be a flat day with the President speaking 3 hours after the close. Economic numbers were disappointing with Initial Claims coming in higher than expected and above 400,000, again. Despite the news, the market was even for much of the session before giving up 1% in the final hour of trading.
We listened to Obama’s speech and we blocked out the entire world as we tuned-in to hear what he could do to possibly save his presidency. We won’t rehash our remarks but Friday was showing a negative open despite the throwing of a $450 billion kitchen sink into the Wall Street equation. The bulls were holding ground for much of the first half but the market went into a tailspin on worries that Greece was going to fold on its debt.
The reaction was swift and although the nation’s top brass squelched those rumors, the damage had been done. The bulls put up a good fight and were trying to close the week with a win but the 3% pounding by the bears gave them the victory and the momentum.
The one bright spot is that the bulls did manage to hold our downside targets we listed in Friday’s afternoon update but will it be enough to hold off a plunge to new lows?
The Dow got whacked for 303 points, or 2.7%, on Friday to end at 10,992. The index traded to a low 10,935 but finished right near the 11,000 (black line, green circles) mark which represents short-term support. If the 11,000 level doesn’t hold, look for a test down to 10,800 (red line, black circles). Last week we also listed bear market targets if major support breaks and for the Dow and it was 10,250 (orange line). Resistance will be 11,200-11,350 this week followed by 11,500 (blue line) which was challenged midweek. For the 4-days of trading, the Dow dropped 248 points, or 2.2%, and is down 585 points for the year, or 5.1%.
The S&P 500 got torched for 32 points, or 2.7%, and settled at 1,154. On Thursday, we mentioned a test down to 1,150 (orange line, green circles) would come into play if the index failed to hold 1,200 (red line, purple circles) and 1,175 which are now resistance levels. There is further risk down to 1,125-1,120 (black line, orange circles) and we said 1,090 (green line) could come into play if we do test a bear market. For the week, the S&P fell 20 points, or 1.7%, and is off 8.2% YTD, or 103 points.
The Nasdaq declined 61 points, or 2.4%, and finished at 2,467. The battle at 2,500 (green line, purple circles) was in play for much of the week and we thought there was a chance this level could hold but is now short-term resistance. Tech touched an intraday low of 2,414 (orange line, green circles) on Tuesday which represents near-term support. There is further support at 2,350 on a continued breakdown and the bear market level is at 2,300 (red line, black circles). If the bulls can get past 2,500 then they will target another run back to 2,600 (black line). For the week, the Nasdaq held up well, giving up 0.5%, or only 12 points, but is showing a decline of 7% for 2011, or 185 points.
The S&P Volatility Index (^VIX, 33.92, up 2.10) made some massive swings as well last week and popped 12% Friday. The VIX reached resistance at 40 (black line, red circle) and kissed a high of 40.74 intraday which we said would come into play if the market tested the lows again. The bulls will try to get the VIX back near 30 (green line, orange circles) and under but a continued selloff would mean a parabolic move higher.
The market has been in a 6-week trading range since the beginning of August and could remain that way for a few more weeks. The Fed will be speaking on the 20th and they could spur a rally if they pump some more money into the system.
As far as this week, September stock options expire on Friday which will also be Triple-Witching day. This means other types of options will be expiring which can add to the volatility as traders battle over strike prices.
President Obama is expected to introduce the jobs bill to Congress on Monday so let’s see what happens. Either the Keystone Kops have learned something or we face a few weeks of another possible stalemate between members of Congress which could cause the market to drift lower.
= = = = = = = = = = = = = = =
Key of Technicals Used In Following Article
|
Bollinger Band |
Bands plotted two standard deviations away from a simple moving average, the closer the price to the upper band, the more overbought the stock is, and the closer the price to the lower band, the more oversold the stock is. |
|
Moving Average |
Average price over a length of time, it is used to spot trends. |
|
MFI (Money Flow Index) |
Increases when money flowing into a stock (positive money flow) is increases with respect to money flowing out of the stock (negative money flow), an MFI of 100 would mean that there is no money flowing out of a stock and only money flowing into the stock. General consensus says an MFI of 80 is overbought and an MFI of 20 is oversold. |
|
RSI (Relative Strength Index) |
Momentum oscillator that measures the speed of directional price movement, general consensus says an RSI of 70 is overbought and an RSI of 30 is oversold. RS = Relative Strength U = Up Days EMA = Exponential Moving Average D = Down Days n = number of days in period |
|
Stochastic %K and %D |
An oscillation in closing prices, the %K is the change in closing price with respect to past high and low of a period, usually 14 days. The %D is the average of the %K values for a past period, usually 3 days. A bearish signal is given when %K crosses below the %D in overbought territory, defined as reading above 80. A bullish signal is given when %K crosses above the %D in oversold territory, defined as reading below 20. |
|
W%R (William’s%R) |
Change in high price to closing price with respect to past high and low of a period, usually 14 days, a reading above 20 is considered overbought territory, and a reading below 80 is considered oversold territory. |
|
Support/Resistance |
These predetermined levels are used to predict when prices will reverse. |
2. NetEase.com (NTES) a Good Play on China’s Online Gaming Boom
NetEase.com (NTES, $47.94, down $0.95) is either a value play or a value trap. A quick look at the stock’s numbers, revenue history, and analysts’ targets make it seem like shares are a value. What the company does and how they make money looks impressive but the short-term technical picture is giving mixed signals.
The $6.29 billion internet and gaming giant based in Beijing, China has been on the tear. China’s second-biggest online game operator has risen 30,456% in the past 10 years, turning a $1,000 investment into $30,456,000. The company provides multi-player online role-playing games including Fantasy Westward Journey, Ghost, Westward Journey Online II, Tian Xia II, Fly for Fun, and Heroes of Tang Dynasty (or Datang). It also has exclusive licenses to World of Warcraft and Starcraft in China. Anyone who has played a role-playing game can say the company’s games are very addictive. In role playing games, a player takes the life of an avatar, a graphic representation of the user’s character. In each game, players enter virtual worlds that exist on game servers in which thousands of players simultaneously connect and interact.
Ghost Online is about supernatural tales based on Strange Tales from a Chinese Studio and ancient classical myths. Its unique randomness system enables players to go on adventures in brand new scenes every day. Datang Online is a martial-arts and real-time combat game based on Chinese chivalrous stories. Tian Xia II is based on Chinese ancient fairy stories and geographical features. In the game, players can raise pets and enjoy other creative game play full of Chinese elements. Fly for Fun, licensed from Korea, is based in a medieval fantasy world. Starcraft is a military-science fiction strategy game, and World of Warcraft allows users to explore the fantasy Warcraft universe. Warcraft has become the most-subscribed and most popular role-playing game in the world. Even adults become hooked to Warcraft.
With its diverse selection of games targeting customers of different user-type and geographic location, the company hopes to appeal to most of the Chinese population. With 1.2 billion people in China, it has a potentially large market. Plus, considering that still only 37% of the population has internet access, compared to 78% for the United States, the company’s market is nowhere near saturated.
Besides gaming, NetEase offers online advertising on its websites and paid listings on its search engine and web directory. Its online mall allows businesses to establish their own storefront on the internet. Through China Mobile and China Unicom, the company also offers wireless services such as news, stock quotes, e-mails, ringtones, instant messages, and matchmaking and interactive games. The company is the largest provider of free email services in China and its website includes news, sports, science and technology, financial markets, and entertainment such as cartoons, games, astrology, and jokes, from over one hundred international and domestic providers.
As the graphs above show, the company’s gaming revenue has been growing steadily over the last five quarters, while the advertising revenue has taken a dive from the 4th quarter of 2010. This could likely be just a cyclical pattern of advertising spending over the course of a year as the 1st quarter advertising revenue still increased from a year ago.
The three-year revenue graph proves that total revenue has been growing steadily. There seems to be a cyclical fall in revenue in the 1st quarter of every year, but revenue picks up after that. Analysts’ estimates for the 3rd quarter (9/11) and the 4th quarter (12/11) are included.
In the 2nd quarter ending June 30, online gaming revenue increased 13.9% quarter-over-quarter and 33.6% year-over-year. Comparing its numbers to its top competitors, the stock is neither the best value wise nor the worst.
SINA = Sina PWRD = Perfect World SOHU = Sohu.com SNDA = Shanda Interactive Entertainment CYOU = Changyou.com Limited
|
|
NTES |
SINA |
PWRD |
SOHU |
SNDA |
CYOU |
|
Price/Sales |
6.51 |
16.13 |
2.25 |
4.26 |
1.90 |
5.41 |
|
Price/Book |
3.59 |
5.19 |
1.62 |
3.35 |
1.39 |
3.65 |
|
Trailing PE |
14.08 |
— |
6.89 |
17.92 |
38.95 |
9.67 |
|
Forward PE |
11.72 |
66.25 |
5.47 |
13.05 |
18.40 |
7.12 |
|
PEG |
0.78 |
5.63 |
0.40 |
1.00 |
1.93 |
0.50 |
|
Revenue Growth (%) |
33.60 |
19.70 |
31.20 |
36.00 |
25.50 |
35.10 |
|
Gross Margin (%) |
66.94 |
57.10 |
82.67 |
73.59 |
59.04 |
88.64 |
|
Current Ratio |
6.23 |
5.39 |
2.84 |
3.51 |
2.81 |
3.72 |
|
Revenue/Market Cap |
0.067 |
0.157 |
0.462 |
0.247 |
0.521 |
0.199 |
|
Cash/Market Cap |
0.281 |
0.120 |
0.360 |
0.282 |
0.723 |
0.217 |
|
EV/Revenue |
4.59 |
13.82 |
1.40 |
2.91 |
0.69 |
3.95 |
|
EV/EBITDA |
9.24 |
66.18 |
3.68 |
7.07 |
3.39 |
6.12 |
|
Return on Equity (%) |
28.30 |
-3.30 |
26.38 |
23.23 |
4.04 |
44.69 |
Source: Numbers calculated from Yahoo Finance
The price/sales and price/book are both the 2nd and 3rd highest respectively, not a great value. However, the PEG is below one and is also the second lowest in the group, a positive sign. Revenue growth is also one of the highest in the group, another positive sign. Interestingly, nearly every member except PWRD has more cash than revenue. One strong point, the current ratio of 6.23 is the best in the group meaning that the company has more than enough current assets to cover its current liabilities. EV/EBITDA is often used to find takeover targets, with companies under five usually being targeted. The large return on equity shows the company is very efficient at generating profits. Experience says that a stock with a high return on equity does well when compared to the general market.
Growth for this year is expected to reach 37.30%, comparing to the industry average of 16.40%. Growth for the next five years is expected to reach 17.54% annually. Sales growth is 46.6%.
Over the last 7 days earnings estimates have been on the rise, a factor that helps boost a company’s stock price. As a side note, NetEase has surprised on earnings over the past 4 quarters.
The stock could also get a boost later this year when social gaming company Zynga goes public. If the IPO is successful, it could boost others in the space. But the biggest boost could come from the government. Last week a JPMorgan Chase analyst noted that China could be done raising interest rates, which could rally all Chinese stocks.
At $48, the stock is near its low target of $45 made by the 20 analysts recorded by Thomson/First Call. Mean target is $57.50; median target is $57; and the high target is $65. Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 1.9, unchanged from a week ago.
|
|
Current Month |
Last Month |
Two Months Ago |
Three Months Ago |
|
Strong Buy |
8 |
8 |
8 |
9 |
|
Buy |
12 |
12 |
10 |
10 |
|
Hold |
5 |
4 |
4 |
5 |
|
Underperform |
0 |
0 |
0 |
0 |
|
Sell |
0 |
0 |
0 |
0 |
= = = = = = = = = = = = = = =
3. Vivus (VVUS) Shares Showing Some Momentum
Investing in Biotech stocks can be a risky endeavor because of clinical trials, cash flow, FDA decisions, and the lack of a strong pipeline. Most Drug companies are one-trick ponies, meaning they only have one drug that is on the market or they only have one drug that looks promising. At the same time, one drug can be worth a billion dollars or more so it isn’t necessarily a need to have others if you have found a cure for a certain type of disease that affects millions.
On the flip side, if a company has only one drug that is in development or only one drug that has been approved then you still need to consider if it is worth an investment. In other words, if a company is working on a treatment for a disease that is already well served by existing drugs, their revenues could be limited.
Of course, when most investors start to look at Biotech or Drug stocks, they immediately start to research which company might have the next cure for cancer, or a cure for cardiovascular diseases, or a drug that will reverse aging. One disease that is often overlooked but leads to a bevy of other health issues is obesity.
The numbers on obese people are staggering with over 70 million Americans falling into this category and 400 million worldwide. Beside the health issues that come with obesity, its economic impact is just as big. Here at home, obesity accounts for nearly 10% of the annual U.S. health bill for Americans, or $150 billion a year.
The problem is only going to get bigger as experts predict in 20 years, obesity could cost nearly $1 trillion. Wow.
There are a few companies that are working on an obesity drug and we first brought you the Vivus (VVUS, $8.40, up $0.32) story nearly three years ago when shares were near $5. Vivus is in a race with Arena Pharmaceuticals (ARNA, $1.25, down $0.03) and Orexigen Therapeutics (OREX, $1.28, down $0.05) to gain approval for a diet drug, and in our view, has the best chance of be the first to cross the finish line.
Vivus plans to attack this market with Qnexa which could easily be a billion dollar a year drug if approved. The drug is currently in Phase 3 trials and could gain FDA (Food and Drug Administration) approval in 2012 if things go according to plan. The FDA rejected the company’s first attempt to take the drug to market on concerns Qnexa could cause birth defect in babies born to women taking it while pregnant.
The company has already reported great observational studies showing no risk of birth defects associated with Qnexa and is currently conducting a second and larger safety study to examine the same birth defect issue. Results are expected in the fourth quarter which means we could hear news as early as October but no later than Christmas. If the study goes well, Vivus plans to resubmit Qnexa to the FDA for a second time for approval which could come sometime in early 2012.
The beauty of Qnexa is not only its ability to fight obesity but the drug is also in Phase 2 clinical trials for its potential as a Type 2 diabetic treatment. Diabetes affects nearly 25 million people in the United States from kids to adults. Estimates put the number of Americans with the disease at 20 million with more than 5 million (or a quarter) not knowing they have the disease. It is estimated that there are nearly 250 million diabetics across the globe so this market is also compelling.
And there’s more.
Qnexa is also being looked at as a possible treatment for obstructive sleep apnea (OSA) which is a sleep-related breathing disorder. OSA a common, yet serious disorder, that affects millions of people who have trouble sleeping due to breathing because of the lack of airflow. Approximately 18 million Americans are believed to have issues when they sleep, though an estimated 90% of the cases are undiagnosed or untreated. Current studies are in Phase 2 trials as well.
Vivus also has plans to get into the erectile dysfunction (ED) market. The company announced positive results from a pivotal phase 3 clinical trial for Avanafil in June and recently submitted an application to the FDA for approval which was accepted. The study met all primary endpoints and indicated that successful intercourse was achieved as early as 15 minutes. A decision on the drug is expected by April 2012.
While Pfizer (PFE, $18.28, down $0.54) remains the 800-pound gorilla in the ED space, Vivus should find a niche with its fast-acting good wood pill. The market for erectile dysfunction grew 7% in 2010 to over $5 billion in sales so there is room for Vivus to make some decent profits if the drug does hit the market.
Avanafil would be a nice addition to the company’s pipeline.
The company does generate some cash but is still losing money on a year-over-year basis. Vivus recently raised $46 million in a direct share offering of nearly 7 million shares near $7 to build up their coffers. This brings the cash and cash equivalents on hand to $160 million which is plenty to get them through 2013.
Vivus would make a great acquisition candidate while shares are in the single-digits and with a market cap of just $675 million, we are expecting just that. We would not be surprised if a takeover offer of $15 starts hitting the rumor mill over the next 3-6 months, especially if the news for Qnexa continues to come in positive.
If the company can get through the FDA’s hurdles for their diet drug, then Vivus will easily trade to the upper teens on any positive developments so the time to make a bid is now.
The company does have a lot riding on Qnexa but even if only one of the drug’s three targeted markets is penetrated, sales could easily reach a billion a year.
The chart for Vivus has been improving with shares moving into a higher trading range with the run past resistance at $8 (black line, red circles). If current levels hold, there is a chance the stock can push $9 (orange line, purple circles) which is the next wave of resistance. From there, Vivus would be on the verge of a breakout.
As you can see, there is additional support at its 200-day moving average (MA) of $7.85 as well but the uptrend could be giving us clues.
Given the strength shares are showing, we think a run to $9 is easily attainable with a shot at $10 by yearend if there are no setbacks with the company’s drugs. The momentum is there for Vivus to have a monster run so these targets could be taken out quickly. Our longer-term price-target (6-12 months) for Vivus is $20 based on Qnexa’s approval for obesity but this could be conservative if the drug can be used for multiple treatment options.
= = = = = = = = = = = = = = =
4. Earnings
The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter. If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week (Quotes are as of Friday’s close, 9/9/11).
MONDAY
Aerosonic (AIM, $3.00, down $0.22), BioDelivery Sciences International (BDSI, $3.23, down $0.04), Brady (BRC, $25.81, down $1.05), Coffee Holding (JVA, $18.29, down $0.12), Crystal Rock Holdings (CRVP, $0.70, Flat), EnviroStar (EVI, $1.30, up $0.04), Farmer Bros (FARM, $4.86, down $0.14), HB Fuller (FUL, $19.94, down $0.44), Marshall Edwards (MSHL, $1.51, down $0.09), Napco Security Technologies (NSSC, $2.63, up $0.14), Natural Alternatives International (NAII, $4.93, Flat), Nobility Homes (NOBH, $7.60, Flat), Optical Cable (OCC, $3.65, Flat), Origin Agritech (SEED, $2.81, down $0.03), Overland Storage (OVRL, $2.65, flat), Pansoft (PSOF, $2.45, up $0.17), Peerless Systems (PRLS, $3.75, up $0.04), Pharmacyclics (PCYC, $11.29, down $0.27), Pizza Inn (PZZI, $2.87, down $0.03), SigmaTron International (SGMA, $3.85, down $0.10), Skilled Healthcare Group (SKH, $4.39, down $0.34), SMF Energy (FUEL, $2.33, up $0.10), Streamline Health Solutions (STRM, $1.85, Flat), ThermoGenesis (KOOL, $1.63, down $0.02), Value Line (VALU, $11.56, down $0.34), Zanett (ZANE, $0.54, up $0.08)
TUESDAY
Best Buy (BBY, $24.50, up $0.30), Champion Industries (CHMP, $1.36, down $0.01), China Metro-Rural Holdings (CNR, $1.26, down $0.01), Cracker Barrel Old Country Store (CBRL, $37.99, down $2.06), Frequency Electronics (FEIM, $10.45, up $0.32), Global Traffic Network (GNET, $13.97, up $0.02), K12 (LRN, $26.35, down $0.84), Oilsands Quest (BQI, $0.21, Flat), Qiao Xing Mobile Communication (QXM, $1.51, down $0.06), Qiao Xing Universal Resources (XING, $1.03, down $0.02), R G Barry (DFZ, $9.13, down $0.67), Schiff Nutrition International (WNI, $9.10, down $0.42), Sutor Technology Group (SUTR, $1.30, down $0.07)
WEDNESDAY
Amrep (AXR, $7.30, Flat), Apogee Enterprises (APOG, $8.36, down $0.35), Ascena Retail Group (ASNA, $26.80, down $0.58), Astrotech (ASTC, $0.74, down $0.02), Cubic Energy (QBC, $0.78, up $0.03), Freeseas (FREE, $1.15, up $0.01), National Technical Systems (NTSC, $4.88, up $0.06), Nevada Gold and Casinos (UWN, $1.90, down $0.04), Oxygen Biotherapeutics (OXBT, $2.24, down $0.02), Pall (PLL, $42.47, dfown $1.56), Paramount Gold And Silver (PZG, $2.38, down $0.16), Pro Dex (PDEX, $1.78, down $0.04), Searchmedia Holdings (IDI, $1.38, up $0.02), Wpcs International (WPCS, $2.09, up $0.03)
THURSDAY
AAR (AIR, $21.39, down $0.70), China Botanic Pharmaceutical (CBP, $0.93, up $0.02), Diamond Foods (DMND, $74.58, down $1.34), Ener1 (HEV, $0.36, down $0.01), Lantronix (LTRX, $1.63, up $0.01), Pier 1 Imports (PIR, $10.57, down $0.40), Research In Motion (RIMM, $29.68, down $1.63), Tier Technologies (TIER, $3.48, down $0.01)
FRIDAY
Isoray (ISR, $1.10, down $0.06), KingtoneWirelessinfo Solution Holding (KONE, $1.10, down $0.10), Netsol Technologies (NTWK, $0.81, down $0.03), Providence And Worcester Railroad (PWX, $11.96, down $0.41), Suffolk Bancorp (SUBK, $8.04, up $0.29), Swift Transportation (SWFT, $7.88, up $0.14)
= = = = = = = = = = = = = = =
5. Weekly Wrap Covered Call Portfolio Update (Closing prices as of 9/9/11)
WEEKLY WRAP CLOSED TRADES for 2011: VVUS +18%, DNDN +9%, PCX +13%, SGEN +26%, TIVO +34%, REDF +11%, PCX +7
Vivus (VVUS, $8.23, down $0.21)
October 9 calls (VVUS111022C00009000, $0.35, down $0.05)
Original Entry Price: $8.45 (9/9/11)
Lowered Price from Selling Options: $8.05
Exit Target: $10+
Return: 2%
Stop Target: None
Action: We wanted to lock in profits on our first VVUS trade in case there is a pullback. Vivus closed above $8 (red line, purple circles) all week which was prior resistance and is now holding as short-term support. Shares could test $7.50 (orange line, green circles) if this level is taken out but we are looking for a run up to $9 (green line, black circles).
We recommended buying the stock at $8.45 on 9/9/11 and for every 100 shares to sell the October 9 calls for 40 cents. This lowered the cost basis to $8.05.
If shares are called away at $9 in mid-October the trade will make 12%.
Clean Energy Fuels (CLNE, $13.29, down $1.12)
September 13 calls (CLNE110917C00013000, $0.70, down $0.80)
Original Entry Price: $12.53 (8/12/11)
Lowered Price from Selling Options: $11.53
Exit Target: $13+
Return: 15%
Stop Target: None
Actions: The September calls expire this Friday and we may or may not get called away on our shares. We would like to keep the position open because Clean Energy could be testing its 52-week high of $17.85 over the next few months.
The stock surged past strong resistance at $14 (black line, red circles) on Thursday, only to give the gains all back on Friday. Support is still strong at $12.50 (green line, purple circles).
We recommended buying the stock at $12.53 on 8/12/11 and for every 100 shares to sell the September 13 calls for $1. This lowered the cost basis to $11.53.
If shares are called away at $13 this week the trade will make 13%.
MGM Resorts (MGM, $10.09, down $0.50)
September 12 calls (MGM110917C00012000, $0.05, down $0.02)
Original Entry Price: $11.73 (8/12/11)
Lowered Price from Selling Options: $10.83
Exit Target: $12+
Return: -7%
Stop Target: None
Action: MGM tested resistance at $11 (orange line, brown circles) on Thursday but fell nearly 5% on Friday and is back near support at $10 (black line, red circles). There is risk down to $9 (green line) if shares don’t rebound this week. MGM owns 80% of the premier properties in Vegas and has its footprints in China. The stock is trading at a forward PE of 2.
We recommended buying the stock at $11.73 on 8/12/11 and for every 100 shares to sell the September 12 calls for 90 cents. This lowered the cost basis to $10.83.
If shares are called away at $12 this week the trade will make 11%.
General Electric (GE, $15.09, down $0.50)
September 16 calls (GE110917C00016000, $0.07, down $0.10)
Original Entry Price: $15.98 (8/12/11)
Lowered Price from Selling Options: $15.23
Exit Target: $18+
Return: -1%
Stop Target: None
Action: We said last week shares would likely test strong support at $15 (green line, red circles) on a continued pullback which is exactly what happened. Resistance at $16 (black line, orange circles) has been tough to overtake while $14.50 (blue line, black circles) serves as near-term support.
We recommended buying the stock at $15.98 on 8/12/11 and for every 100 shares to sell the September 16 calls for 75 cents. This lowered the cost basis to $15.23.
If shares are called away at $16 this week the trade will make 5%.
Newpark Resources (NR, $7.64, down $0.34)
Original Entry Price: $9.45 (7/27/11)
Lowered Price from Selling Options: $8.95
Exit Target: $10+
Return: -15%
Stop Target: None
Action: Shares traded up to $8.18 and $8.19 last week which is just above resistance at $8 (black line, red circles). Short-term support at $7.50 (green line, blue circles) will need to hold or $7 could come into play this week (orange line, brown circles).
We recommended buying the stock at $9.45 on 7/27/11 and for every 100 shares to sell the August 10 calls for 50 cents. This lowered the cost basis to $8.95.
Rambus (RMBS, $10.96, down $0.27)
September 17 calls (RMBS110917C00017000, $0.03, down $0.01)
Original Entry Price: $15.60 (7/22/11)
Lowered Price from Selling Options: $14.95
Exit Target: $20+
Return: -27%
Stop Target: None
Action: Shares are stuck between short-term support (black line, red circle) at $10 and short-term resistance at $12 (green line, orange circles). A break above or below these levels could lead to much larger moves but these options should expire worthless and we will wait to write another call.
We recommended buying the stock at $15.60 on 7/22/11 and for every 100 shares to sell the September 17 calls for 65 cents. This lowered the cost basis to $14.95.
If shares are called away at $17 this week the trade will make 14%.
Symantec (SYMC, $16.05, down $0.43)
Original Entry Price: $18.77 (6/8/11)
Lowered Price from Selling Options: $17.82
Exit Target: $20+
Return: -10%
Stop Target: None
Action: The break above $16 (red line, green circles) represented prior resistance and is holding as short-tem support. There is still risk down to $15 (blue line, orange circles) if current levels don’t hold. We are waiting for a run past resistance at $17 (black line, purple circles) before writing another option.
We recommended buying the stock at $18.77 on 6/8/11 and for every 100 shares to sell the July 19 calls for 60 cents. This lowered the cost basis to $18.17.
On 7/18/11 we recommended selling the August 20 calls for 35 cents which lowered the cost basis to $17.82.
Rare Element Resources (REE, $8.22, down $0.14)
Original Entry Price: $12.38 (5/31/11)
Lowered Price from Selling Options: $11.23
Exit Target: $15+
Return: -27%
Stop Target: None
Action: Shares tested resistance at $9+ (orange line, green circles) on Monday but before fading the rest of the week. REE could test $7.50 (black line, red circles) on a break below $8. We are waiting for a breakout above $10 before selling another call option.
We recommended buying the stock at $12.38 on 5/31/11 and for every 100 shares to sell the July 12 calls for $1.15. This lowered the cost basis to $11.23.
AKS Steel Holding (AKS, $8.22, down $0.42)
Original Entry Price: $15.93 (5/2/11)
Lowered Price from Selling Options: $14.58
Exit Target: $20+
Return: -44%
Stop Target: None
Action: AKS was flat for the week but traded up to $9 (red line, green circles) again which is serving as short-term resistance. There is still a risk down to $6 (black line, blue circles) if shares continue lower. We may add to this position soon to lower our cost basis.
We recommended buying the stock at $15.93 on 5/2/11 and for every 100 shares to sell the May 16 calls for 50 cents. This lowered the cost basis to $15.43.
On 7/1/11 we recommended selling the August 16 call option for $0.85 which lowered the cost basis to $14.58.
American Capital (ACAS, $8.12, down $0.21)
Original Entry Price: $9.73 (4/19/11)
Lowered Price from Selling Options: $8.68
Exit Target: $15+
Return: -6%
Stop Target: None
Action: Shares are right between resistance near $9 (red line, green circles) and support just under $8 (black line, orange circles).
We recommended buying the stock at $9.73 on 4/19/11 and for every 100 shares to sell the June 10 call for 50 cents. This lowered the cost basis to $9.23.
On 7/1/11 we recommended selling the August 10 call option for $0.55 which lowered the cost basis to $8.68.
Cisco Systems (CSCO, $15.82, down $0.47)
November 17 calls (CSCO111119C00017000, $0.60, down $0.10)
Original Entry Price: $17.14 (3/17/11)
Lowered Price from Selling Options: $16.28
Exit Target: $20+
Return: 1%
Stop Target: None
Action: Cisco got an upgrade last week and shares traded to a high of $16.45 (green line, red circles) which represented the next layer of resistance after $16 (black line, orange circles). Strong support lies at $15 (purple line, brown circles).
We recommended buying the stock at $17.14 on 3/17/11 and for every 100 shares to sell the May 18 call for 56 cents. This lowered the cost basis to $16.58.
On 7/22/11 we recommended selling the August 17 calls for 30 cents which lowered the cost basis to $16.28.
On 9/9/11 we recommended selling the November 17 calls for 65 cents which lowered the cost basis to $15.63.
If shares are above $17 by mid-November and we are called away, the trade makes 9%.
Spreadtrum Communications (SPRD, $19.88, down $0.11)
Entry Price: $23.45 (2/7/11)
Lowered Price from Selling Options: $21.48
Exit Target: $30
Return: -7%
Stop Target: None
Action: Spreadtrum surged 8% for the week and reached a high of $20.20 on Thursday and $20.48 on Friday. We mentioned the strong run past resistance at $18 (red line, purple circles) could carry shares to $20 (black line, orange circles) which represents the next battle. A pop past $22 (green line) will be the setup to challenge new highs. The November 20 calls (SPRD111119C00020000, $2.25, up $0.15) would be enough to give us a profit but we think shares could easily trade north of $25 by Christmas so we are going to wait.
Shares opened at $23.43 on 2/7/11 and the March calls could have been sold for 95 cents. This lowered the cost basis to $22.48.
On 4/11/11 we recommended selling the May 22.50 call option for $1.00 which lowered the cost basis to $21.48.
DryShips (DRYS, $2.91, down $0.06)
January 2012 7.50 call (DRYS120121C00007500, $0.05, flat)
Entry Price: $5.25 (1/03/11)
Lowered Price from Selling Options: $4.60
Exit Target: $8
Return: -37%
Stop Target: None
Action: Shares continue to trade north and south of $3 (red line, black circles) and we have a ways to go before challenging the next wave of resistance at $3.60 (green line). However, this is a “cheap” stock and we thinks shares can trade back to $5 in 2012.
DryShips opened at $5.37 on 1/3/11 and shares were at $5.25 shortly after the bell. The January call options could have been sold for 65 cents which lowered the cost basis to $4.60.
If shares are over $7.50 by January 2012, the stock will be “called away” and the trade will make over 60%.
= = = = = = = = = = = = = = =
6. Week Ahead
There are no major economic reports due out on Monday.
Before the bell on Tuesday, the monthly reports on Import/Export Prices will be released. The latest Treasury Budget numbers are due out in the afternoon.
Wednesday is pretty busy with the MBA Mortgage Index and the MBA Mortgage Purchase Index due out before the open along with the Producer Price Index (PPI) and Retail Sales for August. Shortly after trading begins, July’s Business Inventories and the weekly update on Crude Inventories will be released.
Thursday will also be hectic with Initial Claims and Continuing Claims hitting the Street before the open along with the latest Consumer Price Index (CPI) figures for August and the latest update for the Empire State Manufacturing Index. Once trading starts, the Industrial Production and Capacity Utilization numbers will be in focus followed by the Philly Fed Business Index for September later in the afternoon.
We wind down the week with the preliminary Reuters/University of Michigan Consumer Sentiment Index for September, 30 minutes after the open.
]]>






















